Sanofi announced a $625 million capital infusion into its corporate venture unit, Sanofi Ventures, raising total assets above $1.4 billion. The expanded evergreen fund aims to back early to late-stage biotech and digital health companies, with a focus on immunology, rare diseases, neurology, vaccines, AI, and data-driven drug development platforms. This strategic move strengthens Sanofi's commitment to innovative pipelines despite recent setbacks in eczema drug trials, providing long-term flexible funding options aligned with patient impact.